A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: * Preventive therapy with isoniazid for M. tuberculosis. * Maintenance therapy for CMV retinitis. Patients must have: * HIV infection or history of an AIDS-defining condition by CDC criteria. * One documented CD4 count \< 100 cells/mm3 within 12 months prior to study entry. * NO active MAC disease, MAC bacteremia, or active mycobacterial infection (tuberculous or nontuberculous). * NO acute opportunistic infection. * Life expectancy of more than 6 months. * Consent of parent or guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: ALL PATIENTS - * Unexplained fevers, elevation in alkaline phosphatase, pancytopenia, abnormal liver function tests, or odynophagia for which the diagnoses of MAC and fungal infections have not been excluded. * Serious hypersensitivity reactions to macrolides or rifampin. * Unable to tolerate oral medications. FOR FLUCONAZOLE RANDOMIZATION - * Serious hypersensitivity reaction to fluconazole. * Active fungal infection (cryptococcosis, histoplasmosis, blastomycosis, aspergillosis, Candida esophagitis, thrush, vaginal candidiasis). * Positive baseline urine cryptococcal culture. Concurrent Medication: Excluded for fluconazole randomization: * Maintenance therapy for deep fungal infections. * Chronic therapy with ketoconazole or fluconazole.